Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 15/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6614764 | 1.00 | CNR2 (0.40) | CNR2CNR1OPRM1OPRK1MAOA | |
| SCHEMBL1493746 | 0.85 | CNR2 (0.42) | CNR2CNR1OPRM1OPRK1RORC | |
| SCHEMBL1493865 | 0.85 | CNR2 (0.42) | CNR2CNR1OPRM1OPRK1RORC | |
| SCHEMBL2845977 | 0.79 | CNR2 (0.41) | CNR2CNR1OPRM1OPRK1MAOA | |
| SCHEMBL28038908 | 0.79 | CNR2 (0.41) | CNR2CNR1OPRM1OPRK1MAOA | |
| SCHEMBL15129890 | 0.79 | CNR2 (0.41) | CNR2CNR1OPRM1OPRK1MAOA | |
| SCHEMBL25494519 | 0.75 | OPRM1 (0.42) | CNR2CNR1OPRM1OPRK1 | |
| SCHEMBL1347339 | 0.72 | DPP4 (0.53) | — | |
| SCHEMBL15130403 | 0.71 | HDAC8 (0.46) | CNR2MAOAMAOB | |
| SCHEMBL29162891 | 0.71 | CNR2 (0.37) | CNR2CNR1OPRM1OPRK1RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063045-B2 | Fluoropyrrolidines having dipeptidyl peptidase enzyme inhibitory activity | SANOFI-AVENTIS (FR) | 2011-11-22 | — | — | US | disclosed |
| US-20100210838-A1 | FLUOROPYRROLIDINES HAVING DIPEPTIDYL PEPTIDASE ENZYME INHIBITORY ACTIVITY | SANOFI-AVENTIS (FR) | 2010-08-19 | — | — | US | disclosed |
| US-20100160328-A1 | NEW COMPOUNDS USEFUL FOR DPP-IV ENZYME INHIBITION | SANOFI-AVENTIS (FR) | 2010-06-24 | — | — | US | disclosed |
| US-7655663-B2 | Fluoropyrrolidines having dipeptidyl peptidase enzyme inhibitory activity | SANOFI-AVENTIS (FR) | 2010-02-02 | — | — | US | disclosed |
| US-7652021-B2 | (2S)-4,4-difluoro-1-{N-[3-(pyrimidin-2-ylamino)-1-adamantyl]glycyl}pyrrolidine-2-carbonitrile; dipeptidyl peptidase IV enzyme inhibitors; non-insulin dependent diabetes mellitus | SANOFI-AVENTIS (FR) | 2010-01-26 | — | — | US | disclosed |
| EP-1487807-B1 | Cyano-pyrrolidines as DPP-IV inhibitors | SANOFI AVENTIS (FR) | 2009-09-16 | — | — | EP | disclosed |
| US-20080161310-A1 | FLUOROPYRROLIDINES HAVING DIPEPTIDYL PEPTIDASE ENZYME INHIBITORY ACTIVITY | SANOFI-AVENTIS (FR) | 2008-07-03 | — | — | US | disclosed |
| US-7348327-B2 | Compounds | SANOFI-AVENTIS (FR) | 2008-03-25 | — | — | US | disclosed |
| EP-1664031-B1 | ADAMANTANE AND AZABICYCLO-OCTANE AND NONANE DERIVATIVES PROCESS OF THEIR PREPARATION AND THEIR USE AS DPP-IV INHIBITORS | SANOFI AVENTIS (FR) | 2007-12-19 | — | — | EP | disclosed |
| US-20060276487-A1 | New compounds useful for DPP-IV enzyme inhibition | SANOFI-AVENTIS (FR) | 2006-12-07 | — | — | US | disclosed |
| US-20050130981-A1 | Compounds | SANOFI-AVENTIS (FR) | 2005-06-16 | — | — | US | disclosed |
| EP-1487807-A2 | NEW COMPOUNDS | Sanofi-Aventis (FR) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003074500-A2 | N-AMINOACETYL-PYRROLIDINE-2-CARBONITRILES AND THEIR USE AS DDP-IV INHIBITORS | SANOFI-AVENTIS (FR) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161310-A1 | FLUOROPYRROLIDINES HAVING DIPEPTIDYL PEPTIDASE ENZYME INHIBITORY ACTIVITY | DPP4, DPP3, DPP7 | CNR2 4756/4885CNR1 4534/4885OPRM1 1867/4885 |
| US-20050130981-A1 | Compounds | DPP4, DPP3, DPP7 | CNR2 4329/4885CNR1 3647/4885OPRM1 1089/4885 |
| US-20100210838-A1 | FLUOROPYRROLIDINES HAVING DIPEPTIDYL PEPTIDASE ENZYME INHIBITORY ACTIVITY | DPP4, DPP3, DPP7 | CNR2 4756/4885CNR1 4534/4885OPRM1 1867/4885 |
| US-20060276487-A1 | New compounds useful for DPP-IV enzyme inhibition | DPP4, DPP7, DPP9 | CNR2 4635/4885CNR1 4613/4885OPRM1 3387/4885 |
| US-20100160328-A1 | NEW COMPOUNDS USEFUL FOR DPP-IV ENZYME INHIBITION | DPP4, DPP7, DPP9 | CNR2 4635/4885CNR1 4613/4885OPRM1 3387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.